06.17.25 -- STREAM Edition: Improvements In Scaling And Sequencing For Allogeneic Cell Therapies For Oncology

During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies.

Watch part 4 of a four-part series, "Four Common Types Of Cryogenic Studies For Advanced Therapies," to learn about transportation studies.

Discover how to build robust, scalable systems and improve throughput with insights from Quell Therapeutics' Chief Manufacturing Officer, Aaron Vernon.

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.

Discover an end-to-end solution that digitally integrates two automated, functionally closed systems and supports autologous CAR T cell therapy manufacturing from clinical to commercial.

On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures.